Explore › Intervention › Compound beta-blockers
Intervention

Compound beta-blockers

Also known as: Clinician prescribing of beta-blockers for ASCVD patients who have intellectual/developmental disabilities Clinician prescribing of beta-blockers for heart failure patients who have intellectual/developmental disabilities Compound beta-blockers Compound beta-blockers (product) Compound beta-blockers (substance) HF
6 findings 1 paper 4 related entities View in graph →

Related entities

conditions
Atherosclerotic cardiovascular disease risk estimator plus1 Congestive heart failure with right heart failure1
outcomes
Beta blocker therapy declined2
studys
PMC80096952

Findings (50)

None
decline

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Size: adjusted OR 0.66 CI: 95% CI = 0.55-0.79
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Size: adjusted OR 0.66 CI: 95% CI = 0.55-0.79
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Size: adjusted OR 0.66 CI: 95% CI = 0.55-0.79
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Size: adjusted OR 0.66 CI: 95% CI = 0.55-0.79
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Size: adjusted OR 0.66 CI: 95% CI = 0.55-0.79
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Size: adjusted OR 0.66 CI: 95% CI = 0.55-0.79
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Size: adjusted OR 0.66 CI: 95% CI = 0.55-0.79
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Size: adjusted OR 0.66 CI: 95% CI = 0.55-0.79
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Size: adjusted OR 0.66 CI: 95% CI = 0.55-0.79
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Size: adjusted OR 0.66 CI: 95% CI = 0.55-0.79
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Size: adjusted OR 0.66 CI: 95% CI = 0.55-0.79
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Size: adjusted OR 0.66 CI: 95% CI = 0.55-0.79
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Size: adjusted OR 0.66 CI: 95% CI = 0.55-0.79
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Size: adjusted OR 0.66 CI: 95% CI = 0.55-0.79
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Size: adjusted OR 0.66 CI: 95% CI = 0.55-0.79
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Size: adjusted OR 0.66 CI: 95% CI = 0.55-0.79
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Size: adjusted OR 0.66 CI: 95% CI = 0.55-0.79
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Size: adjusted OR 0.66 CI: 95% CI = 0.55-0.79
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Size: adjusted OR 0.66 CI: 95% CI = 0.55-0.79
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Size: adjusted OR 0.66 CI: 95% CI = 0.55-0.79
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Size: adjusted OR 0.66 CI: 95% CI = 0.55-0.79
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Size: adjusted OR 0.66 CI: 95% CI = 0.55-0.79
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Size: adjusted OR 0.66 CI: 95% CI = 0.55-0.79
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Size: adjusted OR 0.66 CI: 95% CI = 0.55-0.79
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Size: adjusted OR 0.66 CI: 95% CI = 0.55-0.79
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Size: adjusted OR 0.66 CI: 95% CI = 0.55-0.79
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Size: adjusted OR 0.66 CI: 95% CI = 0.55-0.79
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Size: adjusted OR 0.65 CI: 95% CI = 0.58-0.73
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Size: adjusted OR 0.65 CI: 95% CI = 0.58-0.73
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Size: adjusted OR 0.65 CI: 95% CI = 0.58-0.73
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Size: adjusted OR 0.65 CI: 95% CI = 0.58-0.73
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Size: adjusted OR 0.65 CI: 95% CI = 0.58-0.73
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Size: adjusted OR 0.65 CI: 95% CI = 0.58-0.73
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Size: adjusted OR 0.65 CI: 95% CI = 0.58-0.73
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Size: adjusted OR 0.65 CI: 95% CI = 0.58-0.73
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Size: adjusted OR 0.65 CI: 95% CI = 0.58-0.73
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Size: adjusted OR 0.65 CI: 95% CI = 0.58-0.73
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Size: adjusted OR 0.65 CI: 95% CI = 0.58-0.73
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Size: adjusted OR 0.65 CI: 95% CI = 0.58-0.73
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Size: adjusted OR 0.65 CI: 95% CI = 0.58-0.73
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Size: adjusted OR 0.65 CI: 95% CI = 0.58-0.73
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Size: adjusted OR 0.65 CI: 95% CI = 0.58-0.73
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Size: adjusted OR 0.65 CI: 95% CI = 0.58-0.73
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Size: adjusted OR 0.65 CI: 95% CI = 0.58-0.73
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Size: adjusted OR 0.65 CI: 95% CI = 0.58-0.73
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Size: adjusted OR 0.65 CI: 95% CI = 0.58-0.73
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Size: adjusted OR 0.65 CI: 95% CI = 0.58-0.73
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Size: adjusted OR 0.65 CI: 95% CI = 0.58-0.73
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Size: adjusted OR 0.65 CI: 95% CI = 0.58-0.73
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Size: adjusted OR 0.65 CI: 95% CI = 0.58-0.73
PMC8009695
Finding details → · Paper → · Graph →

Papers (1)